Loading
Bliss GVS Pharma Limited Stock: price and insider trades · India
1 insider bought shares over the last 90 days, the latest by Clarus Capital I & Others, filed 31 Jul 2026.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€3M
30 ops. · all time
Sell Volume
€619,780
5 ops. · all time
Who traded when
BuySaleGagan Harsh Sharma10 buys1 sale
Gagan Harsh Sharma3 buys
Narsimha Shibroor Kamath2 buys
Vibha Gagan Sharma2 buys
Clarus Capital I & Others1 buy
Gagan Harsh Sharma & PACs1 sale
+3 other insiders
Since the insiders bought
- +271.7%Entry ₹172.90 · Close 22 Oct 2026 ₹642.70
- -5.2%Entry ₹155.47 · Close at T+90 ₹147.38
- +58.3%Entry ₹122.80 · Close at T+365 ₹194.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,751 of 26,286 companies
56.2
score / 100
Value34
Quality79
FCF yld1.2%
Earn yld1.9%
EV/EBITDA29.3x
ROE12%
Gross mgn54%
Net mgn14%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹620.00
Analyst consensus
Income statement
Revenue₹9.2B
Gross profit₹5B54% margin
EBITDA₹2.3B25% margin
Net income₹1.3B13.5% margin
Valuation
PER (trailing)49.2x
P/Book5.5x
Beta1.22
Balance sheet & cash
Market cap₹65.9B
Total debt₹217.5M
Free Cash Flow₹818.9M
Debt / Equity2%
Profitability & ownership
ROE11.6%
ROA5.9%
% insiders54.6%
% institutions8.4%
Last declaration on 6 October 2026
Declarations42 total
50,984,595 shares@ ₹684.0048.66% mcap100.0% of flowEquityPledge CreationSEBI:14b8ff8cd50af9e7dab1428fb561cdfad6f22983
32,436,924 sharesEquity SharesAcquisition of shares - offmarketSEBI:6dddef6eabf01898a9bb9f0627fa20a27e498dbc
5,831,900 sharesEquity SharesSale of Shares - offmarketSEBI:bf05a6359ccd8029fc3599c6dc7b0665ca735766
32,436,924 sharesEquity SharesSale of Shares - offmarketSEBI:f9787474ed22d5269e425db904babe63ee799828
2,132,071 shares-MarketSEBI:7df4a1a991bf50c7cb8978540b6b6cb609606b0f
184,652 shares-MarketSEBI:fa14ab8f9c22a36d6a5ed6a196e5de12b484098e
Canonical exit: 29 Oct 2026 (T+90)
217,123 shares-MarketSEBI:8ad915700283f648daa94e8010a518389fff5819
24,962 shares-MarketSEBI:3157fe3ec7137cb7b228480a044ae40b6bad144a
24,962 shares@ ₹285.00100.0% of flowEquity SharesMarket SaleSEBI:d7e2b7e938457a8bb3ce41dfd0c54049a2b3cde9
217,123 shares@ ₹285.80100.0% of flowEquity SharesMarket SaleSEBI:c5e548057f09bd37bff69964fffc13407d6ccdb1
2,123 shares@ ₹140.94111.1% of flowEquity SharesSEBI:e5331d93a677845be060bde6663945a19b04f748
Canonical exit: 16 Mar 2026 (T+90)
10,000 shares@ ₹144.105.6% of flowEquity SharesSEBI:3d6c2a97a15ffe508a7b9cdb869c2e8e999026c6
Canonical exit: 12 Mar 2026 (T+90)
5,000 shares@ ₹142.102.7% of flowEquity SharesSEBI:6f41458204dda270481a988495937637af1ab0ca
Canonical exit: 15 Mar 2026 (T+90)
2,666 shares@ ₹158.008.1% of flowEquity SharesSEBI:9a5509ecf001cc4a45e85c0b5731ac6ada834afb
Canonical exit: 25 Sept 2025 (T+90)
7,500 shares@ ₹148.8021.3% of flowEquity SharesSEBI:08fc787eeae245382e49b64c55585a34636c850b
Canonical exit: 23 Sept 2025 (T+90)
24,819 shares@ ₹148.617170.6% of flowEquity SharesSEBI:988a6c73274170724029a0c561c9e19ba4801f95
Canonical exit: 24 Sept 2025 (T+90)
26,056 shares@ ₹149.279216.0% of flowEquity SharesSEBI:cb9f30fb380109af0d1037a12a3948ecc9a564d5
Canonical exit: 22 Sept 2025 (T+90)
6,762 shares@ ₹138.27863.8% of flowEquity SharesSEBI:86253f580105cf06d4cc172182970eda521b5c19
Canonical exit: 21 Sept 2025 (T+90)
46,657 shares@ ₹136.701826.7% of flowEquity SharesSEBI:2e39cc6505e8fdfbe561c39078963522b0c1ebad
Canonical exit: 7 Sept 2025 (T+90)
1,970 shares@ ₹136.72941.1% of flowEquity SharesSEBI:71515f8a7ec688867c64ea71ce9d6aabeea741af
Canonical exit: 8 Sept 2025 (T+90)
4,707 shares@ ₹121.48182.4% of flowEquity SharesSEBI:80d2900426a59bb30a3e6f86d849b3cf72e56384
Canonical exit: 20 Aug 2025 (T+90)
41,605 shares@ ₹121.467621.5% of flowEquity SharesSEBI:ff66561d9cc8454c468aac534952e81539146ce4
Canonical exit: 18 Aug 2025 (T+90)
37,258 shares@ ₹121.197719.0% of flowEquity SharesSEBI:9d39608128e8f4236db72ea3755ece78f0f96332
Canonical exit: 19 Aug 2025 (T+90)
25,000 shares@ ₹122.627625.4% of flowEquity SharesSEBI:2a4044aebef0558677feb86250579ff345210ab5
Canonical exit: 19 Jun 2025 (T+90)
75,000 shares@ ₹120.628874.6% of flowEquity SharesSEBI:112fdb3f0ae986dda9a26e5c5c424b9714b9d9c1
Canonical exit: 18 Jun 2025 (T+90)
25 of 42 declarations
About Bliss GVS Pharma Limited
Purchases dominate at Bliss GVS Pharma Limited: 30 purchases (28 with an amount, EUR 2,950,788, median EUR 58,701) against 5 sales, or 86% purchases among open-market trades. Gagan Harsh Sharma, filed as Promoters, submitted 10 filings, all purchases, and 3 more under a second entry, also purchases. The name also appears on the selling side: a sale of EUR 556,030 on May 21, 2026, the largest in the record, with Punita Sharma (Promoter Group), EUR 63,750 the same day.
The three largest purchases: EUR 305,839 for Vibha Gagan Sharma on March 31, 2022, EUR 301,428 for Shruti Vishal Rao on March 30, 2022 and EUR 270,699 for Narsimha Shibroor Kamath on February 24, 2023. From June 9 to 27, 2025, two filers bought for EUR 168,210.
Read moreShow less
An Indian health care and pharma company listed on the Bombay stock exchange, valued at INR 65.9 billion, of which 54.6% is held by filers. 42 filings from 17 filers are published from March 29, 2022 to October 6, 2026, with 17 in 2025. The last twelve months hold 13 filings, of which 4 purchases and 5 sales. Median publication delay: one day. For 29 purchases, the recorded 90-day return has a median of 1.8%, with 55% positive cases, recorded past results, not a forecast.
